Avibactam is a non-β-lactam β-lactamase inhibitor used in combination with ceftazidime for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and hospital or ventilator-acquired pneumonia. This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract infections, including pyelonephritis caused by antibiotic...
- Mechanism
- Curator reviewed
Avibactam is a non-β lactam β-lactamase inhibitor that inactivates some β-lactamases (Ambler class A β-lactamases, including Klebsiella pneumoniae carbapenemases, Ambler class C and some Ambler class D β-lactamases) by a unique covalent and reversible mechanism, and protects ceftazidime from degradation by certain β-lactamases. Avibactam rapidly reaches the periplasm of bacteria at high enough concentrations to restore activity of ceftazidime against ceftazidime-resistant, β-lactamase-producing strains. Avibactam does not decrease the activity of ceftazidime against ceftazidime susceptible organisms.
- Primary indication
- Avibactam as a combination product with ceftazidime (AVYCAZ) is indicated for: In combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus...Curator reviewed · 6 structured indications
- Formula / weight
- C7H11N3O6S · 265.24 g/mol (avg)
- First approval
- United States, 2014 · European Union, 2016
- Code names
- NXL-104
- Brand names
Resolves to
NDCUAPJVLWFHHB-UHNVWZDZSA-NSMILESNC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Avibactam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account